Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple supplements may fight fatigue in advanced lung disease

NCT ID NCT06439875

Symptom relief Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether taking L-arginine and liposomal vitamin C supplements twice daily could reduce fatigue in people with COPD and chronic respiratory failure. 101 patients were randomly assigned to receive the supplements or a placebo during a 28-day pulmonary rehabilitation program. The main goal was to measure changes in fatigue severity using a standard questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-arginine and liposomal vitamin C
What this could lead to
If it works, this could offer a simple supplement to ease fatigue and improve daily life for people with advanced COPD.
What could go wrong
This is a small, completed trial with no phase designation, so results may not be conclusive or widely applicable. Supplements may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

101 people

The number who actually took part.

Started

Jul 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * COPD patients of both sexes complicated by respiratory failure (PaO2 inferior to 60 mmHg while breathing room air) * aged between 40 and 90 years selected from the inpatient/outpatient population admitted to perform a PR program in 12 Italian rehabilitation hospitals. Exclusion criteria: * consuming any ergogenic supplement in the last 2 months; * severe acute exacerbations in the 3 months before enrolment; * clinical instability (pH inferior to 7.35, hemodynamic instability, tachypnea at rest); * lung restrictive diseases; * primitive pulmonary hypertension; * recent lung thromboembolic events; * orthopaedic clinical conditions interfering with exercise; * coronary heart disease; * cardiac failure with reduced ejection fraction; * major cardiac arrhythmias; * neuromuscular diseases; * mini mental state examination (MMSE) \<24; * any prior or current medical problem that would limit the subject participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease Fatigue respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease Respiratory failure

Contacts and locations

Locations

  • Istituti Clinici Scientifici Maugeri IRCCS

    Lumezzane, Brescia, 25065, Italy

  • Istituti Clinici Scientifici Maugeri IRCCS

    Bari, 70124, Italy

  • Istituti Clinici Scientifici Maugeri Irccs

    Telese Terme, Benevento, 82037, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.